TABLE 2.
Past and present phase II/III clinical trials with vaccines in glioblastoma.
| Clinical trial | Duration | Phase | Target/Lysate | Treatment | Control | Indication | Outcome | References |
|---|---|---|---|---|---|---|---|---|
| NCT01498328 ReACT | 2011–2016 | II | EGFRvIII | Bevacizumab + Rindopepimut (n = 33) | Bevacizumab + KLH (n = 35) | rGBM | PFS-6months: 27 vs 11% | (Reardon et al., 2015) |
| NCT00458601 ACT III | 2007–2016 | II | EGFRvIII | SOC + Rindopepimut + GM-CSF (n = 65) | None | ndGBM | PFS-5.5 months: 66% | (Schuster et al., 2015) |
| NCT01480479 ACT IV | 2011–2016 | III | EGFRvIII | Rindopepimut + GM-CSF + TMZ (n = 371) | KLH + TMZ (n = 374) | ndGBM | OS: 20.1 vs 20 months | (Weller et al., 2017) |
| NCT00643097 ACTIVATe | 2007–2016 | II | EGFRvIII | PEP-3-KLH conjugate + GM-CSF (n = 18) | TMZ (n = 17) | ndGBM | PFS-6 months: 67% | (Sampson et al., 2010) |
| NCT01920191 | 2013–2016 | II | TAA | SOC + IMA950/poly-ICLC (n = 19) | None | ndGBM | OS: 19 months | (Migliorini et al., 2019) |
| NCT00766753 | 2006–2016 | II | TAA | αDC1 + poly-ICLC (n = 22) | None | rGBM | PFS-12 months: 40.9% | (Okada et al., 2011) |
| NCT02078648 | 2014–2018 | II | TAA | SL-701 + poly-ICLC + bevacizumab (n = 74) | None | rGBM | OS-12: 37% | (Peereboom et al., 2018) |
| NCT00293423 | 2013–2017 | II | Autologous peptides | HSPPC-96 (n = 41) | None | rGBM | OS-6 months: 90.2% | (Bloch et al., 2014) |
| NCT00905060 | 2009–2014 | II | Autologous peptides | HSPPC-96 + TMZ (n = 46) | None | ndGBM | OS: 23.8 months | (Bloch et al., 2017a) |
| NCT01814813 | 2013–2017 | II | Autologous peptides | HSPPC0-96 + bevacizumab (n = 59) | Bevacizumab (n = 31) | rGBM | OS: 7.5 vs 10.7 months | (Bloch et al., 2017b) |
| NCT00045968 | 2006–2016 | III | Tumor lysate | DCVax-L + TMZ (n = 232) | Autologous PBMC + TMZ (n = 99) | ndGBM | PFS-2 months: 46.2% PFS-3 months: 25.4% | (Liau et al., 2018) |